Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Erratum: Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer (Oncotarget (2017) 8 41 (69779-69796))

Lookup NU author(s): Maryam Zanjirband Zanjirband, Professor Nicola CurtinORCiD, Emeritus Professor John LunecORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Publication metadata

Author(s): Zanjirband M, Curtin N, Edmondson RJ, Lunec J

Publication type: Note

Publication status: Published

Journal: Oncotarget

Year: 2024

Volume: 15

Pages: 142-142

Online publication date: 22/02/2024

Acceptance date: 02/04/2018

ISSN (electronic): 1949-2553

URL: https://doi.org/10.18632/oncotarget.28523

DOI: 10.18632/oncotarget.28523

PubMed id: 38386812


Share